Drug profile · INN
maralixibat chloride
LIVMARLI
maralixibat chloride (LIVMARLI) is a ileal bile acid transporter inhibitor. Associated with Mirum Pharmaceuticals International B.V.. Route of administration: oral. Current US regulatory status: approved.
Drug details — maralixibat chloride
- US status
- approved
- Class
- Alimentary tract and metabolism (A05)
- Route
- ORAL
- Patents
- 4
- Programs
- 9
- Data quality
- 0.89
Quick answer
maralixibat chloride (LIVMARLI) is a ileal bile acid transporter inhibitor. Associated with Mirum Pharmaceuticals International B.V.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Ileal bile acid transporter inhibitor
Primary target: Ileal sodium/bile acid cotransporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is maralixibat chloride?
maralixibat chloride (LIVMARLI) is a ileal bile acid transporter inhibitor. Associated with Mirum Pharmaceuticals International B.V.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for maralixibat chloride?
LIVMARLI is a marketed brand name for maralixibat chloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of maralixibat chloride?
maralixibat chloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.